Current topics in melanoma, Curr Opin Oncol, vol.19, pp.116-136, 2007. ,
Adaptive, and Acquired Resistance to Cancer Immunotherapy, Cell, vol.168, pp.707-730, 2017. ,
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma, N Engl J Med, vol.371, pp.1877-88, 2014. ,
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial, Lancet, vol.386, pp.444-51, 2015. ,
Improved overall survival in melanoma with combined dabrafenib and trametinib, N Engl J Med, vol.372, pp.30-39, 2015. ,
Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma, N Engl J Med, vol.377, pp.1813-1836, 2017. ,
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance, Cell, vol.162, pp.1271-85, 2015. ,
Functions of DNA methylation: Islands, start sites, gene bodies and beyond, Nat Rev Genet, vol.13, pp.484-92, 2012. ,
Melanoma epigenetics: novel mechanisms, markers, and medicines, Lab Invest, vol.94, pp.822-860, 2014. ,
Epigenetics: A Landscape Takes Shape, Cell, vol.128, pp.635-643, 2007. ,
The nucleosome : a little variation goes a long way, Biochem Cell Biol, vol.84, pp.505-512, 2006. ,
Histone variants: Emerging players in cancer biology, Cell Mol Life Sci, vol.71, pp.379-404, 2014. ,
Lateral Thinking: How Histone Modifications Regulate Gene Expression, Trends Genet, vol.32, pp.42-56, 2016. ,
The molecular hallmarks of epigenetic control, Nat Rev Genet, vol.17, pp.487-500, 2016. ,
Regulation of nucleosome dynamics by histone modifications, Nat Struct Mol Biol, pp.259-66, 2013. ,
Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome, Nat Genet, vol.39, pp.311-319, 2007. ,
Super-Enhancers in the Control of, Cell Identity and Disease. Cell, vol.155, pp.934-981, 2013. ,
SWI/SNF complex in cancer, Nat Genet, pp.178-187, 2017. ,
Writers and readers of histone acetylation: Structure, mechanism, and inhibition, Cold Spring Harb Perspect Biol, vol.6, p.18762, 2014. ,
, Bivalent Chromatin Structure Marks Key Developmental Genes in Embryonic Stem Cells. Cell, vol.125, pp.315-341, 2006.
Genome-wide maps of chromatin state in pluripotent and lineage-committed cells, Nature, vol.448, pp.553-60, 2007. ,
BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma, Curr Biol, vol.15, pp.249-54, 2005. ,
A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation. Science (80-), vol.351, p.2197, 2016. ,
In Vivo genetic screens of patient-derived tumors revealed unexpected frailty of the transformed phenotype, Cancer Discov, vol.6, pp.650-63, 2016. ,
KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation, Oncotarget, vol.4, pp.2144-53, 2013. ,
SETDB1: A novel KAP-1-associated histone H3, lysine 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic genes by KRAB zinc-finger proteins, Genes Dev, vol.16, pp.919-951, 2002. ,
Methyl-CpG binding protein MBD1 couples histone H3 methylation at lysine 9 by SETDB1 to DNA replication and chromatin assembly, Mol Cell, vol.15, pp.595-605, 2004. ,
The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset, Nature, vol.471, pp.513-520, 2011. ,
Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target, Int J Cancer, vol.145, pp.3462-77, 2019. ,
The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors, Nat Commun, vol.6, p.6051, 2015. ,
EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation, Cancer Cell, vol.34, pp.69-84, 2018. ,
Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth, Oncotarget, vol.6, pp.2928-2966, 2015. ,
An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation, Nat Med, vol.22, pp.632-672, 2016. ,
NF-kB2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2, Oncogene, vol.35, pp.2735-2780, 2016. ,
Targeting EZH2 in cancer Kimberly, Nat Med, vol.22, pp.128-162, 2016. ,
C-Myc is required for BRAFV600E-induced epigenetic silencing by H3K27me3 in tumorigenesis, Theranostics, vol.7, pp.2092-107, 2017. ,
The Double Bromodomain Proteins Brd2 and Brd3 Couple Histone Acetylation to Transcription, Mol Cell, vol.30, pp.51-60, 2008. ,
Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151, Pigment Cell Melanoma Res, vol.27, pp.1126-1163, 2014. ,
The epigenetic regulator I-BET151 induces BIM-dependent apoptosis and cell cycle arrest of human melanoma cells, J Invest Dermatol, vol.134, pp.2795-2805, 2014. ,
BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy, Cancer Res, vol.73, pp.6264-6276, 2013. ,
Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene, Mol Cell, vol.68, pp.731-775, 2017. ,
Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitorresistant melanoma, EMBO Mol Med, vol.10, p.8446, 2018. ,
Erasers of histone acetylation: The histone deacetylase enzymes, Cold Spring Harb Perspect Biol, vol.6, p.18713, 2014. ,
Systematic Epigenomic Analysis Reveals Chromatin States Associated with Melanoma Progression, Cell Rep, vol.19, pp.875-89, 2017. ,
The INK4?/ARF locus and melanoma, Oncogene, vol.22, pp.3092-3100, 2003. ,
Epigenetic regulation of p14ARF and p16INK4A expression in cutaneous and uveal melanoma, Biochim Biophys Acta -Gene Regul Mech, vol.1849, pp.247-56, 2015. ,
Valproic acid induces apoptosis, p16INK4Aupregulation and sensitization to chemotherapy in human melanoma cells, Cancer Biol Ther, vol.6, pp.185-91, 2007. ,
Inhibition of histone deacetylases in cancer therapy: Lessons from leukaemia, Br J Cancer, vol.114, pp.605-616, 2016. ,
Histone deacetylase inhibitors as anticancer drugs, Int J Mol Sci, vol.18, p.1414, 2017. ,
The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity, Melanoma Res, vol.23, pp.341-349, 2013. ,
HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma, Int J Cancer, vol.142, pp.1926-1963, 2018. ,
Vorinostat induces reactive oxygen species and dna damage in acute myeloid leukemia cells, PLoS One, vol.6, p.20987, 2011. ,
An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential, Cell, vol.173, pp.1413-1438, 2018. ,
Use of the Nitrile Oxide Cycloaddition (NOC) reaction for molecular probe generation: A new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6, J Med Chem, vol.51, pp.4370-4373, 2008. ,
Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth, J Med Chem, vol.55, pp.9891-9900, 2012. ,
Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation, Mol Oncol, vol.9, pp.1447-57, 2015. ,
Essential role of HDAC6 in the regulation of PD-L1 in melanoma, Mol Oncol, vol.10, pp.735-50, 2016. ,
Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas, Cancer Res, vol.65, pp.2260-2268, 2005. ,
Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma, Mod Pathol, vol.28, pp.884-94, 2015. ,
HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy, Cancer Res, vol.79, pp.2947-61, 2019. ,
Modulation of antigen-presenting cells by HDAC inhibitors: Implications in autoimmunity and cancer, Immunol Cell Biol, vol.90, pp.55-65, 2012. ,
Histone deacetylases and the immunological network: Implications in cancer and inflammation, Oncogene, vol.29, pp.157-73, 2010. ,
Advances and Challenges of HDAC Inhibitors in Cancer Therapeutics, Adv Cancer Res, vol.138, pp.183-211, 2018. ,
Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-oyl]-benzyl}-carbamate in pretreated metastatic melanoma, Melanoma Res, vol.18, pp.274-282, 2008. ,
MAPK pathway suppression unmasks latent dna repair defects and confers a chemical synthetic vulnerability in BRAF-, NRAS-, and NF1 -mutant melanomas, Cancer Discov, vol.9, pp.526-571, 2019. ,
A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth, Cell, vol.141, pp.583-94, 2010. ,
Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells, Cancer Cell, vol.23, pp.811-836, 2013. ,
Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma, Cancer Cell, vol.33, pp.322-358, 2018. ,
Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors, Nat Commun, vol.9, p.53, 2018. ,
Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylation, Nat Cell Biol, vol.18, pp.1090-101, 2016. ,
H3K27 demethylase JMJD3 employs the NF-?B and BMP signaling pathways to modulate the tumor microenvironment and promote melanoma progression and metastasis, Cancer Res, vol.76, pp.161-70, 2016. ,
A landscape of driver mutations in melanoma, Cell, vol.150, pp.251-63, 2012. ,
SWI/SNF chromatin remodeling enzymes in melanocyte differentiation and melanoma, Crit Rev Eukaryot Gene Expr, vol.24, pp.151-61, 2014. ,
Heterogeneous SWI/SNF chromatin remodeling complexes promote expression of microphthalmia-associated transcription factor target genes in melanoma, Oncogene, vol.29, pp.81-92, 2010. ,
Transcription factor MITF and remodeller BRG1 define chromatin organisation at regulatory elements in melanoma cells, Elife, vol.4, p.6857, 2015. ,
Chromatin remodellers Brg1 and Bptf are required for normal gene expression and progression of oncogenic Braf-driven mouse melanoma, Cell Death Differ, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02359493
Chromatin-Remodelling Complex NURF Is Essential for Differentiation of Adult Melanocyte Stem Cells, PLoS Genet, vol.11, p.1005555, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-02163718
Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny, Oncogene, vol.30, pp.2307-2325, 2011. ,
Senescent cells develop a parp-1 and nuclear factor-?B-associated secretome (PNAS), Genes Dev, vol.25, pp.1245-61, 2011. ,
CD271 is an imperfect marker for melanoma initiating cells, Oncotarget, vol.5, pp.5272-83, 2014. ,
Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells, Oncogene, vol.31, pp.2461-70, 2012. ,
Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotype, Genes Dev, vol.32, pp.448-61, 2018. ,
URL : https://hal.archives-ouvertes.fr/inserm-02528273
Decreased expression of the chromatin remodeler ATRX associates with melanoma progression, J Invest Dermatol, vol.134, pp.1768-72, 2014. ,
SWI/SNF proteins as targets in cancer therapy, J Hematol Oncol, vol.7, p.81, 2014. ,
The histone variant macroH2A suppresses melanoma progression through regulation of CDK8, Nature, vol.468, pp.1105-1114, 2010. ,
Histone H3.3 and its proteolytically processed form drive a cellular senescence programme, Nat Commun, vol.5, p.5210, 2014. ,
Histone Variant H2A.Z.2 Mediates Proliferation and Drug Sensitivity of Malignant Melanoma, Mol Cell, vol.59, pp.75-88, 2015. ,
The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?, Curr Oncol Rep, vol.13, pp.479-87, 2011. ,
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma, N Engl J Med, vol.367, pp.107-121, 2012. ,
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma, Nature, vol.467, pp.596-605, 2010. ,
Mutations of the BRAF gene in human cancer, Nature, vol.417, pp.949-54, 2002. ,
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations, N Engl J Med, vol.367, pp.1694-703, 2012. ,
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation, N Engl J Med, vol.364, pp.2507-2523, 2011. ,
Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib, J Clin Oncol, vol.34, pp.871-879, 2016. ,
Targeted agents and immunotherapies: Optimizing outcomes in melanoma, Nat Rev Clin Oncol, vol.14, pp.463-82, 2017. ,
Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance, Nat Commun, vol.3, p.724, 2012. ,
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E), Nature, vol.480, pp.387-90, 2011. ,
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation, Nature, vol.468, pp.968-72, 2010. ,
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K, Cancer Cell, vol.18, pp.683-95, 2010. ,
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation, Nature, vol.468, pp.973-980, 2010. ,
MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway, Pigment Cell Melanoma Res, vol.30, pp.328-366, 2017. ,
Recurrent tumor cell-intrinsic andextrinsic alterations during mapki-induced melanoma regression and early adaptation, Cancer Discov, vol.7, pp.1248-65, 2017. ,
Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma, Nat Med, vol.22, pp.1056-61, 2016. ,
Tumor-associated B-cells induce tumor heterogeneity and therapy resistance, Nat Commun, vol.8, p.607, 2017. ,
Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor, Melanoma Res, vol.22, pp.466-72, 2012. ,
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study, Eur J Cancer, vol.91, pp.116-140, 2018. ,
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance, Nature, vol.494, pp.251-256, 2013. ,
Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin ?1/FAK Signaling, Cancer Cell, vol.27, pp.574-88, 2015. ,
Therapy-induced tumour secretomes promote resistance and tumour progression, Nature, vol.520, pp.368-72, 2015. ,
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations, Cell, vol.141, pp.69-80, 2010. ,
A stress-induced early innate response causes multidrug tolerance in melanoma, Oncogene, vol.34, pp.4545-4545, 2015. ,
KDM5B promotes drug resistance by regulating melanoma-propagating cell subpopulations, Mol Cancer Ther, vol.18, pp.706-723, 2019. ,
Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance, Nature, vol.546, pp.431-436, 2017. ,
Genome-scale CRISPR-Cas9 knockout screening in human cells, Science, vol.343, pp.84-91, 2014. ,
Sirtuins: Molecular traffic lights in the crossroad of oxidative stress, chromatin remodeling, and transcription, J Biomed Biotechnol, p.368276, 2011. ,
SIRT1 promotes proliferation and inhibits the senescence-like phenotype in human melanoma cells, Oncotarget, vol.5, pp.2085-95, 2014. ,
A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity, Oncogene, vol.34, pp.531-537, 2014. ,
The role of SIRT6 in tumors, Haematologica, vol.103, 2018. ,
SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling, Nat Commun, vol.9, p.3440, 2018. ,
The sirtuin SIRT6 blocks IGF-Akt signaling and development of cardiac hypertrophy by targeting c-Jun, Nat Med, vol.18, pp.1643-50, 2012. ,
MEK-independent survival of B-RAFV600Emelanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720, Clin Cancer Res, vol.17, pp.721-751, 2011. ,
Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells, Cancer Res, vol.70, pp.6670-81, 2010. ,
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNA-damaging agents, Haematologica, vol.103, pp.80-90, 2018. ,
Melanoma and the tumor microenvironment, Curr Oncol Rep, vol.10, pp.439-485, 2008. ,
Identification of essential genes for cancer immunotherapy, Nature, vol.548, pp.537-579, 2017. ,
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer ,
, lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC), J Immunother Cancer, vol.6, p.39, 2018.
IFN-?-related mRNA profile predicts clinical response to PD-1 blockade, J Clin Invest, vol.127, pp.2930-2970, 2017. ,
Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group, J Immunother Cancer, vol.5, p.95, 2017. ,
Trained immunity: A program of innate immune memory in health and disease. Science (80-), vol.352, p.1098, 2016. ,
Immunometabolic Pathways in BCG-Induced Trained Immunity, Cell Rep, vol.17, pp.2562-71, 2016. ,
Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science (80-), vol.345, p.1251086, 2014. ,
Epigenetics and immunotherapy: The current state of play, Mol Immunol, vol.87, pp.227-266, 2017. ,
Epigenetic mechanisms of tumor resistance to immunotherapy, Cell Mol Life Sci, vol.75, pp.4163-76, 2018. ,
The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy, Cell Rep, vol.20, pp.854-67, 2017. ,
A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science (80-), vol.359, pp.770-775, 2018. ,
, Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade. Cell, vol.174, pp.549-63, 2018.
Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824, Cancer Res, vol.69, pp.8693-8702, 2009. ,
Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models, Oncoimmunology, vol.4, p.1019978, 2015. ,
HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics, J Immunother Cancer, vol.7, p.33, 2019. ,
Variates of survival in metastatic uveal melanoma, J Clin Oncol, vol.23, pp.8076-80, 2005. ,
Focus on cutaneous and uveal melanoma specificities, Genes Dev, vol.31, pp.724-767, 2017. ,
Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4, Oncotarget, vol.7, pp.4624-4655, 2016. ,
Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma, Nat Genet, vol.48, pp.675-80, 2016. ,
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi, Nature, vol.457, pp.599-602, 2009. ,
Mutations in GNA11 in Uveal Melanoma, N Engl J Med, vol.363, pp.2191-2200, 2010. ,
Punctuated evolution of canonical genomic aberrations in uveal melanoma, Nat Commun, vol.9, p.116, 2018. ,
Metastatic disease from uveal melanoma: Treatment options and future prospects, Br J Ophthalmol, vol.101, pp.38-44, 2017. ,
Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB, Nature, vol.465, pp.243-250, 2010. ,
Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma, Clin Cancer Res, vol.18, pp.408-424, 2012. ,
Role of histone H2A ubiquitination in Polycomb silencing, Nature, vol.431, pp.873-881, 2004. ,
A Histone H2A Deubiquitinase Complex Coordinating Histone Acetylation and H1 Dissociation in Transcriptional Regulation, Mol Cell, vol.27, pp.609-630, 2007. ,
Deubiquitylation of histone H2A activates transcriptional initiation via trans-histone cross-talk with H3K4 di-and trimethylation, Genes Dev, vol.22, pp.37-49, 2008. ,
BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma, BMC Cancer, vol.13, p.371, 2013. ,
BAP1 Loss Is Associated with DNA Methylomic Repatterning in Highly Aggressive Class 2 Uveal Melanomas, Clin Cancer Res, vol.25, pp.5663-73, 2019. ,
The polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors, Cell Cycle, vol.9, pp.2663-73, 2010. ,
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma, Oncologist, vol.12, pp.1247-52, 2007. ,
Suberoylanilide hydroxamic acid blocks self-renewal and homotypic aggregation of inflammatory breast cancer spheroids, Cancer, vol.116, pp.2760-2767, 2010. ,
In vitro and in vivo anti-uveal melanoma activity of JSL-1, a novel HDAC inhibitor, Cancer Lett, vol.400, pp.47-60, 2017. ,
Combined inhibition of CDK and HDAC as a promising therapeutic strategy for both cutaneous and uveal metastatic melanoma, Oncotarget, vol.9, pp.6174-87, 2018. ,
Class III-specific HDAC inhibitor Tenovin-6 induces apoptosis, suppresses migration and eliminates cancer stem cells in uveal melanoma, Sci Rep, vol.6, p.22622, 2016. ,
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: A randomized clinical trial, JAMA -J Am Med Assoc, vol.311, pp.2397-405, 2014. ,
Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT), J Clin Oncol, vol.36, pp.1232-1241, 2018. ,
HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma, Clin Cancer Res, vol.25, pp.5686-701, 2019. ,
c-FLIP, a master anti-apoptotic regulator, Exp Oncol, vol.34, pp.176-84, 2012. ,
Class I-specific histone deacetylase inhibitor MS-275 overrides TRAIL-resistance in melanoma cells by downregulating c-FLIP, Int Immunopharmacol, vol.21, pp.439-485, 2014. ,
Loss of BAP1 function leads to EZH2-dependent transformation, Nat Med, vol.21, pp.1344-1353, 2015. ,
PR-Set7 is a nucleosome-specific methyltransferase that modifies lysine 20 of histone H4 and is associated with silent Chromatin, Mol Cell, vol.9, pp.1201-1214, 2002. ,
Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status, Nat Med, vol.22, pp.577-585, 2016. ,
Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: Mechanisms and potential clinical implications, Clin Cancer Res, vol.15, pp.3947-57, 2009. ,